Physician profile
Michael Polo
NPI 1942347257
$9,440.08
in general payments reported to CMS, 2019-2025
26 companies · $2,564 in 2025
The $2,564 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $1,193 · 2021: $1,856 · 2022: $412 · 2023: $452 · 2024: $1,063 · 2025: $2,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.83 |
| Education | $327.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,630.01 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $842.59 | 2019-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $800.98 | 2019-2025 | |
| Allergan, INC. | $742.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $711.22 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $632.39 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $631.46 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $560.98 | 2019-2025 | Rexulti |
| Lundbeck LLC | $414.77 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $393.71 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $345.53 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $266.30 | 2019-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $261.55 | 2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $241.54 | 2021-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $184.31 | 2019-2025 | Fanapt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $140.03 | 2021-2025 | Loreev Xr |
| Brainsway USA INC | $135.97 | 2025 | Deep Tms |
| Acadia Pharmaceuticals INC | $94.97 | 2022-2025 | Nuplazid |
| Merck Sharp & Dohme LLC | $82.57 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $75.40 | 2019 | |
| Jazz Pharmaceuticals INC. | $72.11 | 2021-2022 | |
| Neuronetics, INC. | $68.48 | 2019-2020 | |
| Shire North American Group INC | $33.53 | 2019 | |
| Avanir Pharmaceuticals, INC. | $28.36 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.70 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Polo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.